SPYRE THERAPEUTICS, INC. (SYRE) Operating income 2016–2025
SPYRE THERAPEUTICS, INC. (SYRE) annual operating income history from SEC filings — each fiscal year as reported.
-$209.6MFY2025 · since FY2016: -$21.9M → -$209.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$209.6M | -0.5% |
| FY2024 | -$208.6M | +13.9% |
| FY2023 | -$242.3M | -185.8% |
| FY2022 | -$84.8M | -29.1% |
| FY2021 | -$65.6M | +19.4% |
| FY2020 | -$81.5M | -1.4% |
| FY2019 | -$80.3M | -76.7% |
| FY2018 | -$45.5M | -64.3% |
| FY2017 | -$27.7M | -26.3% |
| FY2016 | -$21.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More SYRE financial trends
SYRE RevenueSYRE Net incomeSYRE Net marginSYRE Gross profitSYRE Gross marginSYRE Operating marginSYRE Operating cash flowSYRE Free cash flowSYRE Capital expendituresSYRE Return on equitySYRE Stock buybacksSYRE Dividends paidSYRE Total assetsSYRE Total liabilitiesSYRE Shareholders’ equitySYRE overview →